Beta Glucan and Rheumatoid Arthritis (RA)

Preview this chapter:

Beta Glucan and Rheumatoid Arthritis (RA), Page 1 of 1

< Previous page | Next page > /docserver/preview/fulltext/9789815039238/chapter-16-1.gif

<div&gt;Rheumatoid arthritis is encountered in 3 out of 10000 people every year&lt;/div&gt;<div&gt;worldwide. It is usually seen between the ages of 35 and 50. If precautions are not&lt;/div&gt;<div&gt;taken, it may lead to synovial inflammation, destruction of bone and cartilage. Finally&lt;/div&gt;<div&gt;disability occurs in the later stages of the disease. It can shorten the patient's life span&lt;/div&gt;<div&gt;by 10 years. The previous studies show that β-glucan alone decreased both the hind&lt;/div&gt;<div&gt;paw swelling and the arthrogram on days 21 and 28 of supplementation in rats. In vivo&lt;/div&gt;<div&gt;studies lead to the potential application of (1→3)-β-d-glucan derivatives in treating&lt;/div&gt;<div&gt;human rheumatoid arthritis </div&gt;